Advocacy intelligence hub — real-time data for patient organizations
Komzifti: FDA approved
treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options
Great Ormond Street Hospital for Children NHS Foundation Trust
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
National Cancer Institute (NCI) — PHASE1
Sawa Ito, MD — PHASE2
Vanflyta: FDA approved
in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test
Masonic Cancer Center, University of Minnesota — PHASE2
Rezlidhia: FDA approved
treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance9
REZLIDHIA
Rigel
Idhifa
Servier Pharmaceuticals
VANFLYTA
Daiichi Sankyo
RYDAPT
Novartis
VYXEOS
Jazz
GRAFAPEX
Unknown
Idamycin PFS
Pfizer
Daurismo
Pfizer
VYXEOS ; Vyxeos ; Vyxeos
Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
Komzifti
(ziftomenib)Orphan drugKura Oncology, Inc.
Menin Inhibitor [EPC]
12.1 Mechanism of Action Ziftomenib is a menin inhibitor that blocks the interaction of menin and lysine [K]-specific methyltransferase 2A (KMT2A). Ac...
Vanflyta
(quizartinib)Orphan drugDaiichi Sankyo, Inc.
12.1 Mechanism of Action Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite A...
Rezlidhia
(olutasidenib)Orphan drugRigel Pharmaceuticals, Inc.
12.1 Mechanism of Action Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible ID...
VYXEOS
(Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection)Orphan drugCelator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
Mylotarg
(Gemtuzumab ozogamicin)Orphan drugWyeth Pharmaceuticals, Inc., a Pfizer Company
CD33-directed Immunoconjugate [EPC]
12.1 Mechanism of Action Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 a...
Idhifa
(enasidenib)Orphan drugCelgene Corporation
12.1 Mechanism of Action Enasidenib is a small molecule inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib targets the mutant IDH2 ...
Rydapt
(RYDAPT)Orphan drugNovartis Pharmaceuticals Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays hav...
VENCLEXTA
(venetoclax)Orphan drugstandardAbbVie, Inc
BCL-2 Inhibitor [EPC]
12.1 Mechanism of Action Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpressio...
Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.
Mesothelin (MSLN) is a glycosylphosphatidylinositol-anchored cell surface protein that is overexpressed in several solid tumors and in one-third of pediatric acute myeloid leukemia (AML) cases. It rep...
CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.
AML is an aggressive haematological malignancy characterised by uncontrolled proliferation and differentiation arrest of myeloid progenitor/stem cells. Conventional treatment methods principally entai...
The emerging role of plasmacytoid dendritic cell proliferation in acute myeloid leukemia.
The mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm represents a clonal proliferation of plasmacytoid dendritic cells within myeloproliferative and myelodysplastic di...
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children's Oncology Group (COG) Phase III trial AAML1831 based on...
CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.
Therapies leveraging chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) are limited by the scarcity of leukemia stem cell (LSC)-specific antigens. Here, we found that CD96 is exp...
The Exosome Landscape in Acute Myeloid Leukemia: From Molecular Mechanisms to Translational Frontiers.
Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy arising from the oncogenic transformation of hematopoietic stem and progenitor cells, resulting in clonal expansion ...
He Huang, MD
Zhejiang University
📍 Hanzhou, Zhejiang
Sylvain Chantepie, MD
University Teaching Hospital of Caen
Minocher Battiwalla, MD, MD
National Institutes of Health- NHLBI
📍 NASHVILLE, TN
Corey Cutler, MD, MPH, F.N.P
Dana-Farber Cancer Institute
📍 PARK CITY, UT
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Heng Mei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology